SILO PHARMA, INC. Deferred Revenue, Revenue Recognized
SILO PHARMA, INC. (SILO) reported Deferred Revenue, Revenue Recognized of $838 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2026-08-13
- SILO PHARMA, INC. deferred revenue, revenue recognized for the quarter ending 2024-03-31 was $838.00, a 95.12% decline year-over-year.
- SILO PHARMA, INC. deferred revenue, revenue recognized for the quarter ending 2023-03-31 was $17.19K, a 0.00% change year-over-year.
- SILO PHARMA, INC. deferred revenue, revenue recognized for the quarter ending 2022-03-31 was $17.19K, a 0.01% decline year-over-year.
- SILO PHARMA, INC. deferred revenue, revenue recognized for the quarter ending 2021-09-30 was $17.19K.
- SILO PHARMA, INC. deferred revenue, revenue recognized for fiscal 2021 was $68.75K.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month | Deferred Revenue, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $838.00 10-Q · filed 2026-08-13 | ||||
| 2025-06-30 | $1.68K 10-Q · filed 2026-08-13 | ||||
| 2024-03-31 | $838.00 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $26.61K 10-Q · filed 2024-05-13 | ||||
| 2023-06-30 | $34.38K 10-Q · filed 2023-08-11 | ||||
| 2023-03-31 | $17.19K 10-Q · filed 2023-05-12 | ||||
| 2022-12-31 | $17.19K 10-Q · filed 2023-05-12 | $68.75K 10-K · filed 2023-03-24 | |||
| 2022-09-30 | $51.56K 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | $34.38K 10-Q · filed 2023-08-11 | ||||
| 2022-03-31 | $17.19K 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | $68.75K 10-K · filed 2023-03-24 | ||||
| 2021-09-30 | $17.19K 10-Q · filed 2021-11-10 | $51.56K 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $17.19K 10-Q · filed 2021-08-13 | $34.38K 10-Q · filed 2021-08-13 | |||
| 2021-03-31 | $17.19K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |